Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC for ARDS in COVID-19
NCT04456361Phase 1Active, not recruiting
- Sponsor
- Instituto de Medicina Regenerativa
- Start
- Apr 2020
- Primary completion
- Feb 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in acute respiratory distress syndrome (ARDS), sponsored by Instituto de Medicina Regenerativa. Primary endpoints: Oxygen saturation at Day 14, Respiratory distress symptoms based on Berlin definition at Day 14 and 3 more. Started Apr 2020; status: active, not recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04456361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04456361.